Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00905060 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT00905060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00905060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
June 29, 2009
Completion date
June 3, 2014
Enrollment
70 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors